{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:26Z","timestamp":1787440946488,"version":"build-2736575974"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018998","name":"IReL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018998","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001634","name":"University of Galway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119533","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:54:37Z","timestamp":1779274477000},"page":"119533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review"],"prefix":"10.1016","volume":"200","author":[{"given":"Oran","family":"McNamara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Delany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-4956","authenticated-orcid":false,"given":"Andrea","family":"Kwakowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2026.119533_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.952161","article-title":"Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990-2019","volume":"10","author":"Ding","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00003495-198428050-00003","article-title":"Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use","volume":"28","author":"Ward","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2026.119533_bib4","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fnins.2019.00310","article-title":"Off-Label Use of Bumetanide for Brain Disorders: An Overview","volume":"13","author":"Kharod","year":"2019","journal-title":"Front Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119533_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders","volume":"40","author":"Ben-Ari","year":"2017","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1073858412438697","article-title":"The GABA Excitatory\/Inhibitory Shift in Brain Maturation and Neurological Disorders","volume":"18","author":"Ben-Ari","year":"2012","journal-title":"Neuroscientist"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030396","article-title":"The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis","volume":"11","author":"Ben-Ari","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/bdd.2390","article-title":"Heterogeneous brain distribution of bumetanide following systemic administration in rats","volume":"45","author":"L\u00f6scher","year":"2024","journal-title":"Biopharm. & Drug Dispos."},{"key":"10.1016\/j.biopha.2026.119533_bib9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1021\/jm00287a014","article-title":"Aminobenzoic Acid Diuretics. 2.1 24-Substituted-3-amino-5-sulfamylbenzoic Acid Derivatives","volume":"14","author":"Feit","year":"1971","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119533_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/bmj.1.5794.211","article-title":"Bumetanide: Potent New \"Loop\" Diuretic","volume":"1","author":"Asbury","year":"1972","journal-title":"Br. Med. J."},{"key":"10.1016\/j.biopha.2026.119533_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/B978-0-323-76177-2.00041-6","article-title":"Pharmacologic therapies","author":"Kandasamy","year":"2022","journal-title":"Goldsmith's. Assist. Vent. Neonate"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.pharmthera.2012.07.010","article-title":"Drug transport by Organic Anion Transporters (OATs)","volume":"136","author":"Burckhardt","year":"2012","journal-title":"Pharm. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.joto.2016.10.001","article-title":"Ototoxic effects and mechanisms of loop diuretics","volume":"11","author":"Ding","year":"2016","journal-title":"J. Otol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0022-3565(25)30849-9","article-title":"Study of the sites and mechanism of action of bumetanide in man","volume":"201","author":"Jayakumar","year":"1977","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib15","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/s41467-022-30407-3","article-title":"Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119533_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuropharm.2012.05.045","article-title":"Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments","volume":"69","author":"Loscher","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2026.119533_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108910","article-title":"CNS pharmacology of NKCC1 inhibitors","volume":"205","author":"Loscher","year":"2022","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.24124","article-title":"A Novel Prodrug-Based Strategy to Increase Effects of Bumetanide in Epilepsy","volume":"75","author":"T\u00f6llner","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2026.119533_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)30556-2","article-title":"A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog","author":"Cohen","year":"1976","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"15","key":"10.1016\/j.biopha.2026.119533_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells11152419","article-title":"A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders","volume":"11","author":"Delpire","year":"2022","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF01065171","article-title":"The pharmacokinetics and pharmacodynamics of bumetanide in normal subjects","volume":"10","author":"Marcantonio","year":"1982","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"11","key":"10.1016\/j.biopha.2026.119533_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/j.1552-4604.1981.tb05664.x","article-title":"Metabolism of Bumetanide","volume":"21","author":"Schwartz","year":"1981","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/11596620-000000000-00000","article-title":"Clinical Pharmacology of the Loop Diuretics Furosemide and Bumetanide in Neonates and Infants","volume":"14","author":"Pacifici","year":"2012","journal-title":"Pediatr. Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/epi.12620","article-title":"Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures","volume":"55","author":"Puskarjov","year":"2014","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib25","article-title":"Bidirectional Regulation of GABA(A) Reversal Potential in the Adult Brain: Physiological and Pathological Implications","volume":"14","author":"Kim","year":"2024","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031344","article-title":"Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders","volume":"28","author":"Lam","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1152\/physrev.2000.80.1.211","article-title":"Sodium-Potassium-Chloride Cotransport","volume":"80","author":"Russell","year":"2000","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2026.119533_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107754","article-title":"Functional characterization of novel bumetanide derivatives for epilepsy treatment","volume":"162","author":"Auer","year":"2020","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.biopha.2026.119533_bib29","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.chempr.2020.06.017","article-title":"Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders","volume":"6","author":"Savardi","year":"2020","journal-title":"Chem"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib30","doi-asserted-by":"crossref","first-page":"E1618","DOI":"10.1073\/pnas.1716871115","article-title":"Restoring GABAergic inhibition rescues memory deficits in a Huntington\u2019s disease mouse model","volume":"115","author":"Dargaei","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119533_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fncel.2018.00101","article-title":"Chloride Homeostasis in Neurons With Special Emphasis on the Olivocerebellar System: Differential Roles for Transporters and Channels","volume":"12","author":"Rahmati","year":"2018","journal-title":"Front Cell Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119533_bib32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.trechm.2021.05.004","article-title":"Cation-coupled chloride cotransporters: chemical insights and disease implications","volume":"3","author":"Portioli","year":"2021","journal-title":"Trends Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119533_bib33","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1093\/cercor\/bhac470","article-title":"Expression patterns of NKCC1 in neurons and non-neuronal cells during cortico-hippocampal development","volume":"33","author":"Kurki","year":"2023","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.biopha.2026.119533_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neubiorev.2018.05.001","article-title":"Chloride transporters and GABA polarity in developmental, neurological and psychiatric conditions","volume":"90","author":"Schulte","year":"2018","journal-title":"Neurosci. & Biobehav. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1073\/pnas.1213680110","article-title":"Activation of 5-HT2A receptors upregulates the function of the neuronal K-Cl cotransporter KCC2","volume":"110","author":"Bos","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib36","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.celrep.2014.05.022","article-title":"Kainate Receptors Coexist in a Functional Complex with KCC2 and Regulate Chloride Homeostasis in Hippocampal Neurons","volume":"7","author":"Mahadevan","year":"2014","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.celrep.2016.03.013","article-title":"The Timing of the Excitatory-to-Inhibitory GABA Switch Is Regulated by the Oxytocin Receptor via KCC2","volume":"15","author":"Leonzino","year":"2016","journal-title":"Cell Rep."},{"issue":"40","key":"10.1016\/j.biopha.2026.119533_bib38","doi-asserted-by":"crossref","first-page":"37542","DOI":"10.1074\/jbc.M206293200","article-title":"A Regulatory Locus of Phosphorylation in the N Terminus of the Na-K-Cl Cotransporter, NKCC1*","volume":"277","author":"Darman","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"46","key":"10.1016\/j.biopha.2026.119533_bib39","doi-asserted-by":"crossref","first-page":"16783","DOI":"10.1073\/pnas.0508307102","article-title":"WNK3 modulates transport of Cl- in and out of cells: Implications for control of cell volume and neuronal excitability","volume":"102","author":"Kahle","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"324","key":"10.1016\/j.biopha.2026.119533_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005050","article-title":"Chloride Sensing by WNK1 Involves Inhibition of Autophosphorylation","volume":"7","author":"Piala","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biopha.2026.119533_bib41","series-title":"Jasper's Basic Mechanisms of the Epilepsies","first-page":"1467","article-title":"Ionic Mechanisms of Ictogenic Disinhibition: All GABA Signaling Is Local","author":"Staley","year":"2024"},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tins.2017.03.006","article-title":"Chloride Dysregulation, Seizures, and Cerebral Edema: A Relationship with Therapeutic Potential","volume":"40","author":"Glykys","year":"2017","journal-title":"Trends Neurosci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/1073858402238515","article-title":"GABA and glutamate in the human brain","volume":"8","author":"Petroff","year":"2002","journal-title":"Neuroscientist"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABA(A) receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit","year":"2021","journal-title":"J. Genet Eng. Biotechnol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119533_bib45","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1523\/JNEUROSCI.16-17-05415.1996","article-title":"Stoichiometry of a recombinant GABAA receptor","volume":"16","author":"Chang","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2026.119533_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117112","article-title":"Regional balance between glutamate+glutamine and GABA+ in the resting human brain","volume":"220","author":"Steel","year":"2020","journal-title":"NeuroImage"},{"issue":"30","key":"10.1016\/j.biopha.2026.119533_bib47","doi-asserted-by":"crossref","first-page":"11088","DOI":"10.1523\/JNEUROSCI.1234-11.2011","article-title":"Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia","volume":"31","author":"Hyde","year":"2011","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119533_bib48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrn920","article-title":"Excitatory actions of gaba during development: the nature of the nurture","volume":"3","author":"Ben-Ari","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41398-020-01027-6","article-title":"Environmental regulation of the chloride transporter KCC2: switching inflammation off to switch the GABA on?","volume":"10","author":"Pozzi","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib50","article-title":"The structural basis of function and regulation of neuronal cotransporters NKCC1 and KCC2","volume":"4","author":"Zhang","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.biopha.2026.119533_bib51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3389\/fneur.2019.01407","article-title":"Role of NKCC1 and KCC2 in Epilepsy: From Expression to Function","volume":"10","author":"Liu","year":"2019","journal-title":"Front Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119533_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27082440","article-title":"Beta-Amyloid (A\u03b2(1-42)) Increases the Expression of NKCC1 in the Mouse Hippocampus","volume":"27","author":"Lam","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib53","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/mds.27651","article-title":"Enhanced Na(+) -K(+) -2Cl(-) cotransporter 1 underlies motor dysfunction in huntington's disease","volume":"34","author":"Hsu","year":"2019","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.22696","article-title":"Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia","volume":"71","author":"Talos","year":"2012","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nm.3827","article-title":"Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome","volume":"21","author":"Deidda","year":"2015","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41398-022-01987-x","article-title":"The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder","volume":"12","author":"Li","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"6171","key":"10.1016\/j.biopha.2026.119533_bib57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1247190","article-title":"Oxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring","volume":"343","author":"Tyzio","year":"2014","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2026.119533_bib58","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1007\/s12031-021-01879-7","article-title":"NKCC1 to KCC2 mRNA Ratio in Schizophrenia and Its Psychopathology: a Case\u2013Control Study","volume":"72","author":"Mohaghghegh","year":"2022","journal-title":"J. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib59","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1523\/JNEUROSCI.4447-13.2014","article-title":"The developmental switch in GABA polarity is delayed in fragile X mice","volume":"34","author":"He","year":"2014","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib60","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1038\/s41598-023-32376-z","article-title":"Imbalanced expression of cation-chloride cotransporters as a potential therapeutic target in an Angelman syndrome mouse model","volume":"13","author":"Egawa","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib61","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1542\/peds.2014-4133","article-title":"Paradoxical Benzodiazepine Response: A Rationale for Bumetanide in Neurodevelopmental Disorders?","volume":"136","author":"Bruining","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib62","first-page":"355","article-title":"Paradoxical reactions elicited by diazepam in children with classic autism","volume":"2","author":"Marrosu","year":"1987","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.biopha.2026.119533_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fneur.2017.00469","article-title":"Bumetanide As a Candidate Treatment for Behavioral Problems in Tuberous Sclerosis Complex","volume":"8","author":"Vlaskamp","year":"2017","journal-title":"Front Neurol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119533_bib64","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/0006-2952(82)90111-3","article-title":"The effects of sodium valproate on \u03b3-aminobutyrate metabolism and behaviour in naive and ethanolamine-O-sulphate pretreated rats and mice","volume":"31","author":"Phillips","year":"1982","journal-title":"Biochem. Pharmacol."},{"issue":"334","key":"10.1016\/j.biopha.2026.119533_bib65","first-page":"1","article-title":"The WNK-SPAK\/OSR1 pathway: Master regulator of cation-chloride cotransporters","volume":"7","author":"Alessi","year":"2014","journal-title":"PHYSIOLOGY"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-023-01149-9","article-title":"Neuronal K+-Cl- cotransporter KCC2 as a promising drug target for epilepsy treatment","volume":"45","author":"McMoneagle","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-019-0524-y","article-title":"Alzheimer's disease: risk factors and potentially protective measures","volume":"26","author":"Silva","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib68","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","article-title":"Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration","volume":"11","author":"Verma","year":"2022","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib69","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/cimb46030121","article-title":"Inhibition of NKCC1 Ameliorates Anxiety and Autistic Behaviors Induced by Maternal Immune Activation in Mice","volume":"46","author":"Zhang","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119533_bib71","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1093\/brain\/awad250","article-title":"Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer\u2019s disease mutations","volume":"146","author":"Keramidis","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib72","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5582\/bst.2021.01245","article-title":"Soluble \u03b2-amyloid impaired the GABA inhibition by mediating KCC2 in early APP\/PS1 mice","volume":"15","author":"Zhou","year":"2021","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2026.119533_bib73","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20142","article-title":"APP modulates KCC2 expression and function in hippocampal GABAergic inhibition","volume":"6","author":"Chen","year":"2017","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.biopha.2026.119533_bib74","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s43587-021-00122-7","article-title":"Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer's disease","volume":"1","author":"Taubes","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.biopha.2026.119533_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174771","article-title":"Suppression of hippocampal GABAergic transmission impairs memory in rodent models of Alzheimer's disease","volume":"917","author":"Bie","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119533_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1211571","article-title":"Loop diuretics association with Alzheimer's disease risk","volume":"4","author":"Graber-Naidich","year":"2023","journal-title":"Front Aging"},{"issue":"8","key":"10.1016\/j.biopha.2026.119533_bib77","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1002\/alz.13872","article-title":"Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease","volume":"20","author":"Morales","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of Synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"9996","key":"10.1016\/j.biopha.2026.119533_bib79","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tins.2007.05.004","article-title":"Pathological synchronization in Parkinson's disease: networks, models and treatments","volume":"30","author":"Hammond","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2026.119533_bib81","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55592","article-title":"The effects of chloride dynamics on substantia nigra pars reticulata responses to pallidal and striatal inputs","volume":"9","author":"Phillips","year":"2020","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib82","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41467-018-03802-y","article-title":"GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease","volume":"9","author":"Lozovaya","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/WNF.0000000000000114","article-title":"Bumetanide to Treat Parkinson Disease","volume":"39","author":"Damier","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib84","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/mds.29726","article-title":"A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease","volume":"39","author":"Damier","year":"2024","journal-title":"Mov. Disord."},{"issue":"50","key":"10.1016\/j.biopha.2026.119533_bib85","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.0215-24.2024","article-title":"Restoring Compromised Cl(-) in D2 Neurons of a Huntington's Disease Mouse Model Rescues Motor Disability","volume":"44","author":"Serranilla","year":"2024","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.biopha.2026.119533_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241613021","article-title":"From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research","volume":"24","author":"Jiang","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119533_bib87","first-page":"255","article-title":"Huntington disease","author":"Ghosh","year":"2018","journal-title":"Neurogenet. Part I"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-44151-0","article-title":"Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins","volume":"9","author":"Bonfanti","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1073858420972662","article-title":"Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models","volume":"28","author":"Cepeda","year":"2022","journal-title":"Neuroscientist"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib90","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.21037\/tp.2019.09.09","article-title":"Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation","volume":"9","author":"Hodges","year":"2020","journal-title":"Transl. Pedia"},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib91","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5607\/en.2015.24.4.273","article-title":"Characteristics of Brains in Autism Spectrum Disorder: Structure, Function and Connectivity across the Lifespan","volume":"24","author":"Ha","year":"2015","journal-title":"Exp. Neurobiol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib92","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: A systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib93","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/DBP.0000000000000429","article-title":"Autism Spectrum Disorder in Males with Sex Chromosome Aneuploidy: XXY\/Klinefelter Syndrome, XYY, and XXYY","volume":"38","author":"Tartaglia","year":"2017","journal-title":"J. Dev. Behav. Pedia"},{"issue":"6206","key":"10.1016\/j.biopha.2026.119533_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/science.1256009","article-title":"Response to Comment on \u201cOxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring","volume":"346","author":"Eftekhari","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav0394","article-title":"Pyramidal neuron growth and increased hippocampal volume during labor and birth in autism","volume":"5","author":"Cloarec","year":"2019","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.biopha.2026.119533_bib96","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.biopsych.2017.09.030","article-title":"Maternal Immune Activation Delays Excitatory-to-Inhibitory Gamma-Aminobutyric Acid Switch in Offspring","volume":"83","author":"Corradini","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2026.119533_bib97","article-title":"Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119533_bib98","first-page":"23363","article-title":"Cognitive dysfunction and bumetanide treatment in a valproate-induced rat model of autism","volume":"9","author":"Liu","year":"2016","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"10","key":"10.1016\/j.biopha.2026.119533_bib99","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/aur.3005","article-title":"Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies","volume":"16","author":"Fuentes","year":"2023","journal-title":"Autism Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.10","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib101","first-page":"251","article-title":"Prediction of Behavioral Improvement Through Resting-State Electroencephalography and Clinical Severity in a Randomized Controlled Trial Testing Bumetanide in Autism Spectrum Disorder","volume":"8","author":"Juarez-Martinez","year":"2023","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"12","key":"10.1016\/j.biopha.2026.119533_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.124","article-title":"A randomised controlled trial of bumetanide in the treatment of autism in children","volume":"2","author":"Lemonnier","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib103","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"J. Am. Acad. Child & Adolesc. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority Trial","volume":"60","author":"Sprengers","year":"2021","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41398-020-0692-2","article-title":"Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"15","key":"10.1016\/j.biopha.2026.119533_bib106","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","article-title":"Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dai","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.biopha.2026.119533_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.bspc.2023.105054","article-title":"EEG-based brain connectivity analysis in autism spectrum disorder: Unraveling the effects of bumetanide treatment","volume":"86","author":"Seyed Fakhari","year":"2023","journal-title":"Biomed. Signal Process. Control"},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1362361313514141","article-title":"Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study","volume":"19","author":"Hadjikhani","year":"2015","journal-title":"Autism"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib109","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1038\/s41598-018-21958-x","article-title":"Bumetanide for autism: more eye contact, less amygdala activation","volume":"8","author":"Hadjikhani","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib110","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/apa.15723","article-title":"Bumetanide for autism: Open-label trial in six children","volume":"110","author":"Fernell","year":"2021","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.biopha.2026.119533_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202092","article-title":"The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome","volume":"2014","author":"Grandgeorge","year":"2014","journal-title":"BMJ Case Rep."},{"issue":"12","key":"10.1016\/j.biopha.2026.119533_bib112","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1651-2227.2010.01933.x","article-title":"The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects","volume":"99","author":"Lemonnier","year":"2010","journal-title":"Acta Paediatr."},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib113","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/cap.2015.0045","article-title":"A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism","volume":"25","author":"Du","year":"2015","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib114","doi-asserted-by":"crossref","first-page":"65","DOI":"10.32598\/bcn.2023.3978.1","article-title":"Effect of Bumetanide on Neural Correlates of Emotion Recognition in Youth With Autism Spectrum Disorder: An Event-related Potential Study","volume":"16","author":"Mollajani","year":"2025","journal-title":"Basic Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib115","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018661","article-title":"Successive clinical application of vitamin D and bumetanide in children with autism spectrum disorder: A case report","volume":"99","author":"Feng","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib116","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-An Overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib117","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib118","first-page":"6","article-title":"Epigenetic Factors in Schizophrenia: Mechanisms and Experimental Approaches","volume":"5","author":"F\u00f6cking","year":"2019","journal-title":"Mol. Neuropsychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib119","first-page":"3462","article-title":"Genetics of schizophrenia (Review)","volume":"20","author":"Trifu","year":"2020","journal-title":"Exp. Ther. Med"},{"issue":"21","key":"10.1016\/j.biopha.2026.119533_bib120","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1016\/j.neuron.2024.08.005","article-title":"Network-wide risk convergence in gene co-expression identifies reproducible genetic hubs of schizophrenia risk","volume":"112","author":"Borcuk","year":"2024","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib121","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00048670701213245","article-title":"Gene expression profiling in Brodmann's area 46 from subjetcs with schizophrenia [Article]","volume":"41","author":"Dean","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"14","key":"10.1016\/j.biopha.2026.119533_bib122","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1523\/JNEUROSCI.1423-13.2014","article-title":"Characteristics of the cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and potential relationships to brain function and schizophrenia","volume":"34","author":"Morita","year":"2014","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123158","article-title":"Decreased chloride channel expression in the dorsolateral prefrontal cortex in schizophrenia","volume":"10","author":"Sullivan","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.biopha.2026.119533_bib124","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1523\/JNEUROSCI.4626-11.2012","article-title":"Transcript-specific associations of SLC12A5 (KCC2) in human prefrontal cortex with development, schizophrenia, and affective disorders","volume":"32","author":"Tao","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2026.119533_bib125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fgene.2017.00028","article-title":"Dysbindin Deficiency Modifies the Expression of GABA Neuron and Ion Permeation Transcripts in the Developing Hippocampus","volume":"8","author":"Larimore","year":"2017","journal-title":"Front Genet"},{"issue":"14","key":"10.1016\/j.biopha.2026.119533_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba5032","article-title":"Depolarizing GABAA current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia [Article]","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119533_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchemneu.2021.102040","article-title":"Hippocampal chloride transporter KCC2 contributes to excitatory GABA dysregulation in the developmental rat model of schizophrenia","volume":"118","author":"Atefimanash","year":"2021","journal-title":"J. Chem. Neuroanat."},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/WNF.0000000000000136","article-title":"Treating Schizophrenia With the Diuretic Bumetanide: A Case Report","volume":"39","author":"Lemonnier","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/pcn.12475","article-title":"Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in patients with schizophrenia: A double-blind randomized trial","volume":"71","author":"Rahmanzadeh","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.biopha.2026.119533_bib130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2016.12.002","article-title":"Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial","volume":"184","author":"Rahmanzadeh","year":"2017","journal-title":"Schizophr. Res"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib131","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"issue":"9639","key":"10.1016\/j.biopha.2026.119533_bib132","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib133","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13229-020-00335-4","article-title":"Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study","volume":"11","author":"van Andel","year":"2020","journal-title":"Mol. Autism"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib134","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2026.119533_bib135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nbd.2016.07.014","article-title":"Functional aspects of early brain development are preserved in tuberous sclerosis complex (TSC) epileptogenic lesions","volume":"95","author":"Ruffolo","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2026.119533_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.879451","article-title":"Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label Study","volume":"16","author":"Juarez-Martinez","year":"2022","journal-title":"Front Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib137","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1542\/peds.2010-3500","article-title":"Health Supervision for Children With Fragile X Syndrome","volume":"127","author":"Hersh","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib138","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/ajmg.a.36511","article-title":"Epidemiology of fragile X syndrome: A systematic review and meta-analysis","volume":"164","author":"Hunter","year":"2014","journal-title":"Am. J. Med. Genet. Part A"},{"key":"10.1016\/j.biopha.2026.119533_bib139","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.genom.8.080706.092249","article-title":"The pathophysiology of fragile x syndrome","volume":"8","author":"Penagarikano","year":"2007","journal-title":"Annu Rev. Genom. Hum. Genet"},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1469-1809.2011.00694.x","article-title":"Fragile X syndrome: the FMR1 CGG repeat distribution among world populations","volume":"76","author":"Peprah","year":"2012","journal-title":"Ann. Hum. Genet"},{"issue":"11","key":"10.1016\/j.biopha.2026.119533_bib141","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41380-018-0048-y","article-title":"Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice","volume":"24","author":"He","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"12","key":"10.1016\/j.biopha.2026.119533_bib142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226811","article-title":"Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib143","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2016.01048","article-title":"Fragile X syndrome: A review of clinical management","volume":"5","author":"Lozano","year":"2016","journal-title":"Intractable Rare Dis. Res"},{"issue":"2","key":"10.1016\/j.biopha.2026.119533_bib144","article-title":"Behavioral Problems in Fragile X Syndrome: A Review of Clinical Management","volume":"14","author":"Davidson","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2026.119533_bib145","article-title":"The NKCC1 Inhibitor Bumetanide Restores Cortical Feedforward Inhibition and Lessens Sensory Hypersensitivity in Early Postnatal Fragile X Mice","author":"Kourdougli","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2026.119533_bib146","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/apa.12235","article-title":"Treating Fragile X syndrome with the diuretic bumetanide: a case report","volume":"102","author":"Lemonnier","year":"2013","journal-title":"Acta Paediatr."},{"issue":"11","key":"10.1016\/j.biopha.2026.119533_bib147","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41583-024-00866-2","article-title":"Consequences of trisomy 21 for brain development in Down syndrome","volume":"25","author":"Russo","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib148","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12929-015-0138-y","article-title":"Down syndrome: an insight of the disease","volume":"22","author":"Asim","year":"2015","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib149","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/21622965.2021.2007481","article-title":"Long-term bumetanide administration altered behavioral pattern in mosaic Down\u2019s Syndrome: A case report","volume":"12","author":"Gharaylou","year":"2023","journal-title":"Appl. Neuropsychol. Child"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","article-title":"Unmet clinical needs and burden in Angelman syndrome: a review of the literature","volume":"12","author":"Wheeler","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib151","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","article-title":"Clinical and genetic aspects of Angelman syndrome","volume":"12","author":"Williams","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.biopha.2026.119533_bib152","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1824-7288-36-31","article-title":"Epilepsy in patients with Angelman syndrome","volume":"36","author":"Fiumara","year":"2010","journal-title":"Ital. J. Pedia"},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071430","article-title":"Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD","volume":"12","author":"Erickson","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119533_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.780281","article-title":"Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled Trial","volume":"13","author":"van Andel","year":"2022","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2026.119533_bib155","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(14)70303-5","article-title":"Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1\/2 trial","volume":"14","author":"Pressler","year":"2015","journal-title":"Lancet Neurol."},{"issue":"7-8","key":"10.1016\/j.biopha.2026.119533_bib156","doi-asserted-by":"crossref","first-page":"431","DOI":"10.20452\/pamw.442","article-title":"Drug\u2011induced abnormalities of potassium metabolism","volume":"118","author":"Kokot","year":"2008","journal-title":"Pol. Arch. Intern. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib157","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/00000658-195010000-00014","article-title":"The Effect of Potassium on Deficiency of Intestinal Motility and Gastric Secretion","volume":"132","author":"Webster","year":"1950","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib158","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/psp4.12478","article-title":"Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges","volume":"9","author":"Geerts","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib159","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv. Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41598-017-00325-2","article-title":"Cortical cells reveal APP as a new player in the regulation of GABAergic neurotransmission","volume":"7","author":"Doshina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119533_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101372","article-title":"Neuronal excitation\/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology","volume":"69","author":"Maest\u00fa","year":"2021","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2026.119533_bib162","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1503\/cmaj.120744","article-title":"Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors","volume":"185","author":"Hr\u00f3bjartsson","year":"2013","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.biopha.2026.119533_bib163","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1201982","article-title":"Microglia in Alzheimer's disease: pathogenesis, mechanisms, and therapeutic potentials","volume":"15","author":"Miao","year":"2023","journal-title":"Front Aging Neurosci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119533_bib164","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s43587-023-00424-y","article-title":"Human microglia show unique transcriptional changes in Alzheimer\u2019s disease","volume":"3","author":"Prater","year":"2023","journal-title":"Nat. Aging"},{"issue":"11","key":"10.1016\/j.biopha.2026.119533_bib165","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119533_bib166","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1038\/s41591-023-02566-3","article-title":"Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington\u2019s disease","volume":"29","author":"Wilton","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119533_bib167","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.0b013e318225ae07","article-title":"Proinflammatory cytokines, sickness behavior, and Alzheimer disease","volume":"77","author":"Holmes","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119533_bib168","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001526","article-title":"The NKCC1 ion transporter modulates microglial phenotype and inflammatory response to brain injury in a cell-autonomous manner","volume":"20","author":"T\u00f3th","year":"2022","journal-title":"PLoS Biol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600569X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600569X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:55:09Z","timestamp":1787439309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600569X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":168,"alternative-id":["S075333222600569X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119533","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bumetanide as a potential treatment for neurodegenerative and neurodevelopmental disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119533"}}